Accelerate your drug development program with a clear understanding of your compound’s metabolic profile. Eurofins Discovery provides advanced Phase I and Phase II metabolism studies to evaluate and optimize your compounds metabolic properties, assess drug-drug interaction (DDI) risks, and support confident decision-making from early discovery through preclinical development.
Comprehensive In Vitro Metabolism & Enzyme Assays
Eurofins Discovery provides a comprehensive suite of in vitro metabolism and enzyme assays to evaluate how compounds are metabolized, cleared, and interact with key drug metabolism enzymes. Our platform covers Phase I (CYP450) and Phase II (UGT, GST, SULT, NAT) pathways, delivering a complete view of the metabolic activity of compounds early in drug development.
Using hepatocytes, liver microsomes, and recombinant enzymes, from human and animal species, we generate high-quality data to:
- Identify metabolic pathways and key metabolites
- Assess compound stability and intrinsic clearance
- Evaluate CYP inhibition and induction risk and phase II enzyme pathways
These insights support compound optimization, DDI assessment, and confident candidate selection.
Phase I (CYP450 Enzymes) and Phase II Metabolism
Evaluate oxidative metabolism across key CYP450 isoforms:
- CYP3A4, CYP2D6, CYP2B6, CYP1A2, CYP2C9, CYP2C8, CYP2C19
Assess drug conjugation and detoxification mechanisms in phase II enzymes:
- UGTs, GSTs, SULTs, and NATs
Drug Metabolizing Enzyme Inhibition, Induction, and Phenotyping Studies
- CYP and UGT inhibition: Measure reversible and time-dependent (TDI) inhibition of enzyme activity
- CYP induction: Evaluate gene expression changes via qPCR, enzyme activity assays using HPLC-MS/MS or protein expression levels using advanced MS-based proteomics
- CYP and UGT phenotyping: Explore which enzymes are involved in the metabolism of your compounds
Drug-Drug Interaction (DDI) & ADME Risk Assessment
Metabolism-mediated drug-drug interactions (DDIs) can significantly impact compound pharmacokinetics (PK), affecting drug efficacy and safety. Eurofins Discovery provides targeted studies to identify and mitigate these risks early in development.
We help you:
- Predict drug-enzyme and transporter interactions
- Understand the impact on ADME (absorption, distribution, metabolism, excretion)
- Reduce the risk of costly late-stage failures
Our data supports smarter decision-making, safer study design, and stronger regulatory outcomes.
Regulatory-Aligned CYP450 Testing
Our metabolism studies are conducted in accordance with the International Council for Harmonisation (ICH) M12 guidelines on drug interaction studies, (supported by the FDA, EMA, PMDA, and others), ensuring your data is suitable for global regulatory submissions.
This ensures reliable, regulatory-ready data to support IND-enabling studies and submission success.
Flexible Study Design & Translational Models
Advanced Methods
- Real-time qPCR (mRNA analysis)
- Enzyme activity assays (HPLC-MS/MS)
- MS-based proteomics (Tandem Mass Tag (TMT) LC-MS/MS)
Relevant Biological Systems
- Primary human hepatocytes
- Human recombinant enzymes
- Preclinical species for translational insight
Our flexible design and matrices allows you to scale from early screening to IND-enabling studies.
Why Work with Eurofins Discovery for Metabolism & DDI Studies?
Choosing Eurofins Discovery means reducing risk while accelerating timelines. Our integrated approach combines scientific expertise, advanced technologies, and global capacity to deliver reliable, decision-ready data at every stage of drug development. From early discovery through IND-enabling studies, we help you move faster while maintaining the highest standards of quality and regulatory compliance.
Scientific Depth You Can Trust
Global experts in drug metabolism across multiple therapeutic modalities.
Regulatory-Ready Data
Studies are designed to meet regulatory expectations, supporting IND and NDA submissions.
Speed, Scale & Efficiency
Fast turnaround times with scalable solutions—from single assays to full drug candidate assessment packages.
Integrated Drug Discovery Partner
Seamless support across chemistry, pharmacology, and safety, all within one global organization.
